View Item 

Show simple item record

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer

dc.contributor.authorGianni, L.
dc.contributor.authorRomieu, G.
dc.contributor.authorLichinister, M.
dc.contributor.authorSerrano, S.
dc.contributor.authorMansutti, M.
dc.contributor.authorPivot, X.
dc.contributor.authorMariani, P.
dc.contributor.authorAndre, F.
dc.contributor.authorChan, Arlene
dc.contributor.authorLipatov, O.
dc.contributor.authorChan, S.
dc.contributor.authorWardley, A.
dc.contributor.authorGreil, R.
dc.contributor.authorMoore, N.
dc.contributor.authorProt, S.
dc.contributor.authorPallaud, C.
dc.contributor.authorSemiglazov, V.
dc.date.accessioned2017-01-30T10:38:07Z
dc.date.available2017-01-30T10:38:07Z
dc.date.created2014-11-19T01:13:19Z
dc.date.issued2013
dc.identifier.citationGianni, L. and Romieu, G. and Lichinister, M. and Serrano, S. and Mansutti, M. and Pivot, X. and Mariani, P. et al. 2013. AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer. Journal of Clinical Oncology. 31 (14): pp. 1719-1726.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/4315
dc.publisherAmerican Society of Clinical Oncology
dc.titleAVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
dc.typeJournal Article
dcterms.source.volume31
dcterms.source.number14
dcterms.source.startPage1719
dcterms.source.endPage1726
dcterms.source.issn0732 183X
dcterms.source.titleJournal of Clinical Oncology
curtin.accessStatusFulltext not available


Files in this item

Thumbnail
Name:
203743_109684_Chan_A_Averal.pdf
Size:
1.924Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record